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Abstract
 
Somatic cell mutagenesis is a powerful tool for characterizing receptor systems. We reported
previously two complementation groups of mutant cell lines derived from CD14-transfected
Chinese hamster ovary–K1 fibroblasts defective in responses to bacterial endotoxin. Both
classes of mutants expressed a normal gene product for Toll-like receptor (TLR)4, and fully re-
sponded to stimulation by tumor necrosis factor (TNF)-
 
 
 
 or interleukin (IL)-1
 
 
 
. We identified
the lesion in one of the complementation groups in the gene for MD-2, a putative TLR4 core-
ceptor. The nonresponder phenotype of this mutant was reversed by transfection with MD-2.
Cloning of MD-2 from the nonresponder cell line revealed a point mutation in a highly con-
served region resulting in a C95Y amino acid exchange. Both forms of MD-2 colocalized with
TLR4 on the cell surface after transfection, but only the wild-type cDNA reverted the li-
popolysaccharide (LPS) nonresponder phenotype. Furthermore, soluble MD-2, but not soluble
MD-2
 
C95Y
 
, functioned to enable LPS responses in cells that expressed TLR4. Thus, MD-2 is a
required component of the LPS signaling complex and can function as a soluble receptor for
cells that do not otherwise express it. We hypothesize that MD-2 conformationally affects the
extracellular domain of TLR4, perhaps resulting in a change in affinity for LPS or functioning
as a portion of the true ligand for TLR4.
Key words: sepsis • signal transduction • Toll-like receptors • Gram-negative bacteria • 
lipopolysaccharide
 
Introduction
 
A crucial first line defense against infectious illnesses is the
ability to sense the presence of invading microorganisms.
Gram-negative bacterial sepsis is a common cause of septic
shock and death (1) and may begin abruptly when pathogens
evade mucosal or integumentary structures and invade the
bloodstream. A major part of the systemic inflammatory re-
action is the response to endotoxin (LPS), the main compo-
nent of the outer membrane of Gram-negative bacteria (2).
The conserved lipid A portion of LPS is the structural basis
for the toxic activation of host cells (3). The innate immune
response to LPS is vital to effectively combat an infection, as
animals with impaired LPS recognition are hypersusceptible
to invasive bacterial disease (4). However, in normal hosts,
when the organism burden is very large, an excess of inflam-
matory mediators produced by LPS-activated cells may re-
sult in systemic inflammation and the sepsis syndrome, a
life-threatening condition that is characterized by fever, hy-
potension, compromised cardiac performance, coagulopa-
thy, and multiple end-organ failure (5).
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A Point Mutation in MD-2 Eliminates Endotoxin Signaling
 
The task of defining the composition of the mammalian
cellular receptor complex responsible for the recognition of
LPS is of major scientific interest. The monocyte differenti-
ation antigen, CD14, has long been known to bind LPS as
the first step in endotoxin-induced activation, but the sub-
sequent pathway of signal transduction is less well estab-
lished. CD14 is linked to the plasma membrane of phago-
cytic leukocytes by a glycosyl-phosphatidylinositol anchor,
and can also function as a soluble receptor. The lack of
transmembrane and cytoplasmic domains, as well as the
unique CD14-independent pharmacology of lipid A ana-
logues suggested that a separate signal transduction mole-
cule was necessary for LPS-induced signals (6).
The response to microbial products occurs in lower or-
ganisms. Thus, advances in the understanding of nonmam-
malian biology have had a great impact upon our un-
derstanding endotoxin recognition. 
 
Drosophila 
 
Toll was
initially identified for its role in development (7, 8), but
molecular cloning of Toll led to the realization that the
protein was a member of the IL-1 receptor family. Subse-
quent observations established that Toll expression was in-
volved in innate immunity (9). Mammalian orthologs of
Toll (10, 11), referred to as Toll-like receptors (TLRs),
 
*
 
have been identified and characterized not only for their
role in LPS recognition (12, 13), but for their role in medi-
ating immune responses to a variety of pathogenic organ-
isms (for a review, see reference 14).
TLR4 has been defined as the main cellular signal trans-
ducer for LPS. The first clue that TLR4 was involved in
LPS signal transduction came from the discovery that the
LPS hyporesponsive mouse strains C3H/HeJ and C57BL/
10ScCr have mutations in this gene (12, 15, 16). Cellular
transfection studies demonstrating a gain of function in
TLR4-transfected cells (13), as well as the phenotypic char-
acterization of a mouse with a targeted deletion of TLR4
(17, 18), strengthened the hypothesis that TLR4 is an LPS
signal transducer. Unlike previous studies with CD14 (6),
TLR4 expression was found also to confer the unique spe-
cies-specific pharmacology of human and rodent cells to
certain lipid A analogues, including the lipid A precursor
lipid IVa and 
 
Rhodobacter sphaeroides
 
 lipid A (19, 20). Thus,
TLR4 not only is the primary receptor involved in sensitiz-
ing cells to the presence of LPS, but it also is responsible for
the fine specificity of lipid A recognition.
Although TLR4 has been shown to be a critical compo-
nent for cell activation by LPS, the fully functional LPS sig-
naling complex appears to require additional components.
Recently, a small, extracellular protein known as MD-2
was found to enhance sensitive responses to LPS in cell
lines that were transfected with TLR4. Expression of
TLR4 in MD-2–deficient cells failed to enable these cells
to respond to LPS (21) although other reports suggested
that MD-2 expression might not be absolutely essential (13,
22). Neither a natural mutant in MD-2 nor an animal with
a targeted mutation was available for study. We present
here the first loss of function data, suggesting the nearly ab-
solute importance of MD-2 for LPS signaling either as a
cell-derived or blood-derived LPS receptor component.
We have reported previously two complementation
groups of mutants in a CD14-transfected Chinese hamster
ovary–K1 fibroblast (CHO) cell line that are defective in
LPS signaling (23) but are fully responsive to the cytokines
TNF-
 
 
 
 and IL-1
 
 
 
. TLR4 gene expression is normal in
both groups of cells. However, we identified a point muta-
tion in the gene coding for MD-2 as responsible for the
complete loss of function in one of these mutants. This
mutant, nonfunctional MD-2 still colocalizes on the cell
surface with TLR4. Thus, the LPS receptor complex ap-
pears to require CD14, TLR4, and MD-2 for efficient
function. Furthermore, our analysis of the second comple-
mentation group suggests that the LPS receptor consists of
at least one additional, and as yet unidentified, component.
 
Materials and Methods
 
Cells and Reagents.
 
Reagents were obtained from Sigma-
Aldrich, unless otherwise indicated. PBS, Ham’s F-12, DMEM,
and trypsin-versene mixture were from BioWhittaker. Low en-
dotoxin fetal bovine serum (FBS) was from Hyclone. Ciprofloxa-
cin was a gift from Miles Pharmaceuticals. Hygromycin B was
purchased from Calbiochem. Protein-free LPS derived from 
 
Esch-
erichia coli
 
 strain K-235 was a gift from S. Vogel (Uniformed
Services University of Health Sciences, Bethesda, MD). Synthetic
lipid A (compound 506) was a gift from S. Kusumoto (Osaka
University, Toyonaka, Japan). Human IL-1 was purchased from
Genzyme. CHO cell lines were cultured in Ham’s F-12 contain-
ing 10% FBS, 10
 
 
 
 
 
g/ml ciprofloxacin, and 400 U of hygromycin
per milliliter in 5% saturated CO
 
2
 
 atmosphere at 37
 
 
 
C. HEK 293
cells were cultured in DMEM containing 10% FBS and 10 
 
 
 
g/ml
ciprofloxacin.
 
Cloning of TLR4 from CHO Cells.
 
The sequence of Chinese
hamster TLR4, cloned from both a CHO/CD14 library and
peritoneal macrophages, has been reported previously (GenBank/
EMBL/DDBJ accession no. AF153676; reference 19). Total
RNA was extracted from the cell lines 3E10 (wild-type), 7.7 (a
member of complementation group A), and 7.19 (a member of
complementation group B), respectively, and 1
 
 
 
 
 
g of RNA was
reverse transcribed using Superscript II reverse transcriptase ac-
cording to the manufacturer’s protocol (Life Technologies).
Overlapping fragments of CHO-TLR4 from 3E10, 7.7, and 7.19
were generated using the following primer pairs: 5
 
 
 
-aggttgc-
cactctcacttcc-3
 
 
 
/5
 
 
 
-atgtcaggcttggcagattcactt-3
 
 
 
, basepair (bp) 80–
1,383; and 5
 
 
 
-ttcaaatggcaaaccttagcagtc-3
 
 
 
/5
 
 
 
-atgattctttgcctgagttg-
gtga-3
 
 
 
, bp 1,238–2,992. Multiple fragments from three indepen-
dent PCR reactions from all three cell lines were sequenced at
the Boston Medical Center Core facility (Boston, MA) and in the
laboratory of one of the authors (D.A. Schwartz).
 
Cloning of MD-2 from CHO Cells.
 
PCR was performed on a
previously described cDNA library constructed with the ZAP
Express cDNA Gigapack III Gold cloning kit (Stratagene) from
polyadenylated mRNA derived from CHO/CD14 cells (24).
Cross-species primers were generated based upon the homolo-
gous regions of the published sequences for human and mouse
MD-2. An internal sequence of hamster MD-2 was determined
 
*
 
Abbreviations used in this paper:
 
 bp, basepair; CHO, Chinese hamster
ovary–K1 fibroblast; FBS, fetal bovine serum; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; JNK, c-Jun NH
 
2
 
-terminal kinase; MAP, mi-
togen-activated protein; NF, nuclear factor; TLR, Toll-like receptor. 
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by sequencing the PCR products. This sequence was the basis of
the construction of a set of hamster-specific internal primers. A
combination of plasmid-specific and hamster-specific MD-2
primers were used in a three-step nested PCR, using the CHO/
CD14 cDNA library as a template to derive the full-length
cDNA sequence of CHO MD-2 and the flanking untranslated
regions. Based on these sequences, primers were constructed to
amplify the complete coding region of the gene. For the cloning
of full-length MD-2, total RNA was extracted from the cell lines
3E10 (wild-type), 7.7 (complementation group A), and 7.19
(complementation group B), respectively, and reversed tran-
scribed as described above. One microliter of the resulting cDNA
was used to amplify full-length MD-2 using the primer pair
5
 
 
 
-GTGGAAAGTGTTGGAGATA-3
 
  
 
and 5
 
 
 
-TAAAAACA-
TATATTCTTAATTTATT-3
 
 
 
. Sequences of the resulting
products were confirmed by analyzing the products of two inde-
pendent PCR reactions on multiple sequence runs (at least twice
for each PCR product). Furthermore, the area of the C95Y mu-
tation described in this manuscript has been amplified and se-
quenced separately using internal PCR primers from each of the
three cell lines on at least four additional occasions. The sequence
for MD-2 from the wild-type cell line 3E10 was in complete
agreement with the sequence derived from the CHO cell cDNA
library. The sequence data for hamster MD-2 are available from
GenBank/EMBL/DDBJ under accession no. AF325501.
 
Expression Plasmids.
 
The cDNA of MD-2 was generated by
PCR using site-specific primers and directionally cloned into
XhoI and BamHI sites of the mammalian expression plasmid
pEFBOS (25) to express the Flag epitope at the COOH-terminal
end of the protein. The proper sequence, orientation, and frame
were confirmed by sequencing. The expression plasmid for non-
tagged human TLR4 (hTOLL) in the vector pcDNA3 was a gift
from C. Janeway and R. Medzhitov (Yale University, New Ha-
ven, CT). The pELAM-luc reporter plasmid that transcribes fire-
fly luciferase from a nuclear factor (NF)-
 
 
 
B–dependent promoter
has been described previously (13).
 
Site-directed Mutagenesis of Human MD-2.
 
The cDNA of hu-
man MD-2 was cloned into XhoI and BamHI sites of the mam-
malian expression plasmid pEFBOS as described previously. A
mutant human MD-2
 
C95Y
 
 was generated by site-directed mu-
tagenesis using the primer pair 5
 
 
 
-GCAAAGAAGTTATTTAC-
CGAGGATCTGATGACGATTAC-3
 
 
 
 and 5
 
 
 
-GTAATC-
GTCATCAGATCCTCGGTAAATAACTTCTTTGC-3
 
  
 
and
using the QuikChange mutagenesis kit (Stratagene) according to
the manufacturer’s protocol. Proper introduction of the point
mutation was confirmed by DNA sequencing.
 
Immunoblotting for Activated c-Jun Kinase.
 
Cells were plated at
a density of 5 
 
  
 
10
 
 5 
 
cells per well in six-well dishes and incu-
bated overnight. The following day, the cells were stimulated
with LPS (100 ng/ml), TNF-
 
 
 
 (30 ng/ml), or IL-1
 
 
 
 (5 ng/ml)
for 15 min, followed by lysis of the cell monolayer in 1
 
 
 
 SDS
sample buffer containing 
 
 
 
-mercaptoethanol, sonication for 5 s,
and boiling at 95
 
 
 
C for 5 min. Proteins were immunoblotted
with an Ab specific for phospho-c-Jun NH
 
2
 
-terminal kinase
(JNK; Promega) as described previously (22).
 
Transient Transfection and NF-
 
 
 
B Luciferase Reporter Assay.
 
Cells were plated at a density of 5 
 
 
 
 10
 
5
 
 cells per well in six-well
dishes and incubated overnight. The following day, the cells were
transiently cotransfected with 1
 
 
 
 
 
g of the indicated plasmid plus 1
 
 
 
g of pELAM-luc using the Superfect transfection reagent
(QIAGEN) as per the manufacturer’s protocol (final vol 1.5 ml).
After a 2-h incubation with the DNA, the cells were washed with
PBS and incubated overnight. The next day, cells were stimu-
lated for 5 h. Cell activation was determined by measuring lu-
ciferase activity of the total cellular lysate using an assay kit from
Promega according to the manufacturer’s instructions. Data are
reported as the mean of triplicate determinations 
 
  
 
SD.
 
IL-6 Assay.
 
Cells were seeded at 2 
 
 
 
 10
 
4
 
 cells per well in a
24-well dish and incubated at 37
 
 
 
C overnight. The following
day, cells were washed twice with PBS and stimulated with the
indicated concentrations of LPS or IL-1
 
 
 
 for 7.5 h in a total vol-
ume of 250 
 
 
 
l F12 medium containing 2% FCS. Supernatants
were analyzed for bioactive IL-6 in the B9 cell proliferation assay
as described previously (19, 26). To examine the ability of trans-
fected MD-2 to complement the ability of the CHO/CD14 mu-
tants to release IL-6, cells were seeded at 4 
 
  
 
10
 
4
 
 cells per well in
a 24-well dish and transfected the next day with 0.2 
 
 
 
g of
pcDNA3, the expression plasmid for wild-type or the mutant
MD-2 plasmid using the effectene transfection reagent
(QIAGEN), according to the manufacturer’s protocol. After
overnight incubation, cells were washed twice, stimulated for
7.5 h, and analyzed for bioactive IL-6.
 
Semiquantitative Reverse Transcriptase PCR of MD-2 mRNA.
 
To assess the levels of MD-2 transcript in the cell lines 3E10 and
7.19, total RNA was extracted and 5 
 
 
 
g of RNA was reverse tran-
scribed as above. The resulting cDNA was set up in a master mix
to a final volume of 1 
 
 
 
l cDNA per sample, and primers for ampli-
fication of glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
5
 
 
 
-GTCATCATCTCCGCCCCTTCTGC-3
 
 
 
 and 5
 
 
 
-GATGC-
CTGCTTCACCACCTTCTTG-3
 
 
 
) or full-length MD-2 were
added, respectively. The products of the PCR reactions were re-
moved from the PCR block after the indicated number of cycles,
stored on ice until PCR was completed and resolved by electro-
phoresis on an ethidium bromide stained 2.5% agarose gel.
 
Flow Cytometry Analysis of Cell Surface Expressed MD-2.
 
Cells
were plated at a density of 5 
 
 
 
 10
 
5
 
 per well in six-well dishes and
incubated overnight. The following day, the cells were tran-
siently transfected with MD-2 expression plasmids coding for a
Flag epitope tagged MD-2 and incubated for 24 h. Cells were
harvested by incubating 20 min at 37
 
 
 
C with 1 mM Na
 
2
 
EDTA.
Cells were washed with PBS containing 1% FBS and labeled
with the anti-Flag mAb M2 (20 
 
 
 
g/ml in PBS per 1% FBS;
Sigma-Aldrich) for 30 min on ice. Cells were then washed with
PBS with 1% FBS and counterstained with FITC-conjugated
sheep anti–mouse IgG (1:100 dilution; Sigma-Aldrich) for 30
min on ice, followed by washing in PBS with 1% FBS. The
stained cells were analyzed for Flag epitope expression using a
FACScan™ microfluorimeter with the CELLQuest™ software
package (Becton Dickinson).
 
Immunoprecipitation.
 
HEK 293 cells were seeded at a density
of 5 
 
 
 
 10
 
6
 
 per 100-mm dish, cultured overnight, and transiently
transfected with 8
 
  
 
g of total DNA per condition. After 48 h,
cells were washed once with ice-cold PBS and lysed in buffer
consisting of 50 mM Tris, 1% NP40 (American Bioanalytical),
0.05% CHAPS, 1 mM PMSF, and 0.1% protease inhibitor cock-
tail (Sigma-Aldrich), adjusted to pH 7.5. After incubation on ice
for 30 min, samples were cleared by centrifugation (10 min,
12,000
 
 
 
 
 
g
 
) and supernatants were transferred to chilled fresh
tubes containing 50 
 
 
 
l of anti-Flag M2 agarose in lysis buffer (1:2
packed gel). A 50-
 
 
 
l portion of 2
 
 
 
 sample buffer containing 5%
2-mercaptoethanol was added to each sample. Samples were
boiled for 3 min, spun down (30 s, 10,000 
 
g
 
), and subjected to
SDS-PAGE (10% acrylamide) and Western blot analysis, using a
horseradish peroxidase–conjugated anti-Flag mAb (2 
 
 
 
g/ml M2)
and an horseradish peroxidase–conjugated anti-Myc mAb (0.2
 
 
 
g/ml 9E10; Santa Cruz Biotechnology, Inc.). 
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Results
 
CHO cells lack the differentiation antigen, CD14, and
do not respond to LPS, even though they express TLR4
(19). After transfection
 
 
 
with the cDNA for CD14, the phe-
notype of these cells with respect to endotoxin responses
dramatically changes to resemble phagocytic leukocytes
(27). LPS-responsive CHO/CD14 cells differ from cell
lines of leukocytic origin because they are remarkably easy
to manipulate genetically. Thus, CHO/CD14 are a practi-
cal cell line in which to screen for LPS nonresponder mu-
tants. We selected for abnormalities in one of the key
events in LPS-mediated responses, the activation of the
transcription factor NF-
 
 
 
B (28, 29). The CHO/CD14 cell
lines employed in these investigations were stably trans-
fected with an NF-
 
 
 
B–responsive reporter construct that
was used to discriminate between LPS responder and non-
responder cells derived from methanesulfonic acid ethyl es-
ter (a point mutagen)–treated stocks. The mutants that
were derived were examined by complementation analysis
and assigned to one of two groups, designated group A or
B, each representing a mutation in a different gene (23).
To define the genetic lesion in each of the mutants, we
focused on individual mutants from each of the known
complementation groups: clone 7.7 (a member of the A
complementation group) and clone 7.19 (a member of the
B complementation group).
Wild-type CHO cells transfected with CD14 show a va-
riety of responses to stimulation with LPS, including the
translocation of the transcription factor NF-
 
 
 
B, the activa-
tion of certain mitogen-activated protein (MAP) kinases,
and the release of inflammatory mediators such as arachi-
donic acid (27) and IL-6 (19). To further characterize the
defect in the mutant cell lines, we investigated the activation
of MAP kinases as well as the secretion of IL-6 in response
to stimulation with LPS. Neither of the mutant cell lines
phosphorylated the JNK kinase, one of the MAP kinases
known to be activated by LPS (Fig. 1 A), but showed nor-
mal phosphorylation of the JNK kinase in response to the
cytokines TNF-  and IL-1 . Similarly, both mutants were
impaired in their ability to secrete IL-6 in response to LPS,
whereas they showed a normal response to stimulation with
IL-1  (Fig. 1 B), indicating that the mutation has a broad
effect on the capacity of these cells to show a physiological
response to LPS. Neither of the mutants responded to con-
centrations as high as 5  g LPS per milliliter as assessed by
Figure 1. Mutant CHO-CD14 cells show defects in response to LPS
stimulation, but not in response to the cytokines TNF-  and IL-1 . (A)
Wild-type 3E10 cells and mutant cell lines 7.7 and 7.19 were stimulated
for 15 min with LPS, TNF- , or IL-1 . Cells were lysed and proteins
were resolved by PAGE, electroblotted, and immunoblotted with an Ab
specific for phospho-JNK. The blot shown is representative of three inde-
pendent experiments. (B) Wild-type 3E10 and the mutant cell lines 7.7
and 7.19 were stimulated with LPS or IL-1  at the indicated concentra-
tions for 7.5 h. Supernatants were assayed for bioactive IL-6. The results
shown are mean values of triplicate determinations  SD and are repre-
sentative of three independent experiments.  , 3E10;  , 7.19; X, 7.7.
Figure 2.  Mouse MD-2 confers LPS signaling when expressed in the
LPS nonresponder mutant 7.19, but not on the mutant 7.7. LPS nonre-
sponder mutant cell lines 7.7 (A) and 7.19 (B) were transiently cotrans-
fected with the control plasmid pcDNA3, plasmid coding for human
TLR4 (hTOLL), or mouse MD-2, plus the pELAM-luc reporter plasmid
as described in Materials and Methods. The next day, cells were stimu-
lated with medium alone, 2.5 ng of IL-1  per milliliter, or 5  g of LPS
per milliliter for 5 h. Total cellular lysates were assayed for luciferase ac-
tivity. The results shown are mean values of triplicate determinations
 SD and are representative of three independent experiments.83 Schromm et al.
cotransfection with an NF- B–dependent reporter plasmid
and a control vector, whereas both cell lines responded to
IL-1  (Fig. 2, lanes 1–3) and TNF-  (23). The IL-1 recep-
tor cascade and TLR4 are thought to share many down-
stream signaling components in the NF- B pathway, in-
cluding MyD88 and TRAF6 (30–33). The normal response
of the mutant lines to IL-1  indicates that the mutations re-
sponsible for the LPS nonresponder phenotype affect gene
products in the NF- B pathway that are upstream of these
signaling molecules, presumably receptor components.
First we focused on the genes for TLR2 and TLR4 be-
cause these genes had been reported to be putative signal-
ing receptors for LPS (12, 32, 34). Both genes were cloned
and sequenced from wild-type CHO/CD14 cells. We
found that wild-type CHO cells (as well as normal Chinese
hamsters) do not express functional TLR2 (35), thus indi-
cating that TLR2 expression is not essential for responses to
LPS. Subsequently, this conclusion was confirmed in the
TLR2 knockout mouse (18). In contrast, CHO cells ex-
press a full-length and functional transcript for TLR4 (19).
Cloning of TLR4 from cDNA derived from the mutants
7.7 and 7.19 revealed that both complementation groups
have a functional wild-type transcript for TLR4 (data not
shown) that is identical to the previously reported sequence
of hamster TLR4. Consistent with these data, transient
transfection of the mutants 7.7 and 7.19 with the human
gene for TLR4 failed to have an effect on the phenotype of
these cells (Fig. 2, lanes 4–6).
Next, we sought to determine the role of MD-2 in the
mutant cell lines because of the reports that MD-2 potenti-
ated the activity of TLR4. Transfection with the gene for
mouse MD-2 conferred responsiveness to one of the mu-
tants, clone 7.19, a member of complementation group B.
Transfection of mouse MD-2 into clone 7.7 had no effect.
The ability of mouse MD-2 to impart full responsiveness to
LPS to mutant 7.19 is shown in Fig. 3. Note how the
MD-2 transfected mutant cell line responded similarly to a
wild-type cell line at all concentrations of LPS that were tested.
We cloned hamster MD-2 from all three cell lines by
PCR using reverse-transcribed mRNA as template. Se-
quencing of the gene products from several independent
amplification reactions revealed that the MD-2 transcript
expressed by mutant 7.19 has a single-point mutation at
position 284 of the gene (Fig. 4 A), leading to an amino
acid exchange at position 95 of the protein from a cysteine
to a tyrosine (MD-2C95Y). This C95Y mutation was not
found in mutant 7.7 mRNA (data not shown). Fig. 4 B
shows a partial sequence alignment of the gene for MD-2
from three different species, including the wild-type CHO
cell sequence and the sequence of the mutant 7.19. As
shown, the cysteine residue in position 95 is present in hu-
man, mouse, and hamster MD-2 in a highly conserved re-
gion of the gene. These data underscore both the impor-
tance of this residue and this conserved domain for proper
MD-2 structure and function.
MD-2 is thought to colocalize on the cell surface with
TLR4 (21). One possibility for the LPS nonresponder phe-
Figure 3. Transfection of the mutant 7.19 with mouse MD-2 confers
normal sensitivity to LPS. The parental cell line 3E10 was cotransfected
with plasmid pcDNA3 and the pELAM-luc reporter plasmid (black bars),
as described in the legend to Fig. 2. Similarly, mutant strain 7.19 was
cotransfected with mouse MD-2 and pELAM-luc reporter plasmid
(hashed bars). Subsequently, cells were stimulated with medium alone,
LPS, or IL-1  for 5 h, and cellular lysates were assayed for luciferase ac-
tivity. The results shown are mean values of triplicate determinations
 SD and are representative of three independent experiments.
Figure 4. The mutant 7.19 has a point mutation in the gene coding for
MD-2. (A) MD-2 was sequenced from 3E10, 7.19 and mutant 7.7 (data
not shown); a partial sequence of MD-2 from clone 3E10 and 7.19 is
shown in this figure. Mutant 7.19 has a point mutation at position 284 of
the coding region resulting in a conversion of the codon for cysteine to
tyrosine (codon triplet marked by dashed line). The affected codon corre-
sponds to amino acid position 95 of the protein. (B) Sequence alignment
of bp 268–300 from human, mouse, wild-type CHO MD-2 from 3E10
cells, and MD-2 from the mutant 7.19, showing that the codon for cys-
teine at position 284 in the gene for MD-2, as well as most of the sur-
rounding amino acids, are conserved in a variety of species.84 A Point Mutation in MD-2 Eliminates Endotoxin Signaling
notype observed is that the mutant MD-2 failed to be tran-
scribed, translated, and exported to the cell surface. We used
semiquantitative reverse transcription PCR to determine if
there were gross abnormalities in MD-2 mRNA expression
in the LPS nonresponder CHO/CD14 mutant cell lines and
found that transcript levels of the mutant species of MD-2
were comparable to the parental wild-type cell line (Fig. 5
A). To evaluate if the C95Y mutation prevented protein
expression, we transfected both forms of MD-2 into 7.19
cells. After allowing cells sufficient time for protein expres-
sion to occur, surface expression of the Flag-tagged proteins
was measured by flow microfluorimetry. Although the level
of protein expression was somewhat lower with the mutant
cDNA construct, both forms of MD-2 were well expressed
on the surface of CHO 7.19 (Fig. 5 B). Wild-type MD-2
and mutant MD-2C95Y were expressed on the surface of 41
and 12.5% of the cells, respectively. Transfected cells were
assayed simultaneously for LPS-inducible NF- B activation
using a luciferase reporter construct (Fig. 6 A). In contrast to
the results found with protein expression, the mutant form
of MD-2 failed to enable detectable translocation of NF- B
at a concentration of 1  g of LPS per milliliter, a concentra-
tion that is  100,000-fold greater than ordinarily necessary
to observe activation in wild-type CHO/CD14 cells,
whereas the expression of the wild-type form of MD-2 en-
abled the mutant cell line to respond. The same effect was
observed when transiently transfected cells were assayed for
secretion of the cytokine IL-6 (Fig. 6 B). The expression of
the wild-type form of MD-2 enabled a clear dose-depen-
dent cytokine response to LPS, whereas MD-2C95Y did not.
Thus, the C95Y mutation resulted in a loss of cell signaling
capabilities that was strikingly out of proportion to the di-
minishment in the level of protein bound to the cell surface.
To define the importance of the cysteine residue at posi-
tion 95 for the function of MD-2 in the human immune
response to LPS, a mutant human MD-2 with an identical
mutation was generated by site-directed mutagenesis.
Transient cotransfection of HEK 293 cells with human
TLR4 (hTOLL) and the wild-type human MD-2 or mu-
tant human MD-2C95Y demonstrated that only the wild-
type MD-2 conferred a response to LPS on these cells (Fig.
7), underscoring the probable general importance of the
Figure 5. The mutant MD-2C95Y is transcribed in normal quantities
and expressed on the cell surface. (A) Semiquantitative PCR of MD-2
and GAPDH on reverse transcribed mRNA from 3E10 and 7.19 cells.
(B) FACS® analysis showing surface expression of wild-type MD-2 and
MD-2C95Y in transiently transfected 7.19 cells. Cells were transiently
transfected with MD-2 expression plasmids coding for Flag epitope–
tagged MD-2. After overnight incubation, cells were detached with 1
mM Na2EDTA, washed, and stained with anti-Flag mAb and FITC-con-
jugated sheep anti–mouse IgG secondary Ab as described in Materials and
Methods. Controls were stained with the secondary Ab only.
Figure 6. Transfection of the nonresponder mutant 7.19 with wild-
type CHO MD-2 enables a response to LPS, whereas transfection with
MD-2C95Y does not. (A) The mutant strain 7.19 was cotransfected with
either wild-type hamster MD-2 or hamster MD-2C95Y plus the pELAM-
luc reporter plasmid. The next day cells were stimulated with medium
alone, IL-1 , or LPS at the indicated concentrations for 5 h. Total cel-
lular lysates were assayed for luciferase activity. (B) The mutant strain
7.19 was cotransfected with pcDNA3 control plasmid, wild-type ham-
ster MD-2, or hamster MD-2C95Y. The next day cells were stimulated
with LPS or IL-1  at the indicated concentrations for 7.5 h and super-
natants were assayed for bioactive IL-6. The results shown are mean val-
ues of triplicate determinations  SD and are representative of two inde-
pendent experiments.85 Schromm et al.
cysteine residue at position 95 for cell signaling in all spe-
cies of mammals.
One possible explanation for the lack of LPS responsive-
ness in MD-2C95Y–transfected cells is that the receptor
component, while it is expressed at the cell surface, does
not actually colocalize with TLR4, as has been reported
previously for the wild-type gene product (21). To exam-
ine the physical interaction of the mutant MD-2 with
TLR4, immunoprecipitation analysis was performed on
HEK 293 cells that were transiently transfected with Myc-
tagged human TLR4 plus either Flag-tagged human MD-2
or human MD-2C95Y. Fig. 8 indicates that both wild-type
and MD-2C95Y coimmunoprecipitated with TLR4, imply-
ing that the mechanism involved in the loss of MD-2 func-
tion is more than a simple loss of the physical interaction
between MD-2 and TLR4.
MD-2 is an extracellular protein with neither a pre-
dicted transmembrane domain nor linkage to the cell sur-
face, although its mRNA does encode for a signal se-
quence. We hypothesized that MD-2 might be functional
as a soluble receptor component and that expression of
MD-2 transcript followed by translation and export to an
extracellular site adjacent to TLR4 is not necessary for cells
to respond to LPS. Rather, soluble MD-2 present in
blood-derived products such as serum, or in tissue culture
supernatants, might be sufficient to allow TLR4 to respond
to the presence of LPS. To test this hypothesis, we trans-
fected HEK 293 cells either with wild-type human MD-2
or mutant human MD-2C95Y and collected supernatants
that were enriched in the secreted gene product. After al-
lowing time for protein expression, these supernatants
were then transferred to cell monolayers of HEK 293 cells
that had been cotransfected with TLR4 plus an NF- B–
dependent reporter plasmid. Supernatants derived from
cells that had been transfected with wild-type MD-2 con-
ferred responsiveness on TLR4-expressing cells, whereas
supernatants from cells expressing mutant MD-2C95Y did
not (Fig. 9). These data suggest that MD-2 is not only se-
creted, but that the soluble receptor is functionally active.
However, MD-2C95Y lacks the capability to function as a
soluble receptor component.
Discussion
The ability of bacterial LPS to activate immune cells has
been the subject of intense scrutiny because of its potential
importance in understanding the etiology of the sepsis syn-
drome and other endotoxin-associated diseases. Even re-
Figure 7. A point mutation at position 95 of the human MD-2 gene
abolishes cell activation by LPS. HEK 293 cells were cotransfected with
either wild-type human MD-2 plus human TLR4 (hTOLL) or human
MD-2C95Y plus TLR4 and the pELAM-luc reporter plasmid. The next
day cells were stimulated with medium alone, IL-1 , or LPS at the indi-
cated concentrations for 5 h. Total cellular lysates were assayed for lu-
ciferase activity. The results shown are mean values of triplicate determi-
nations  SD and are representative of three independent experiments.
Figure 8. MD-2 and MD-2C95Y colocalize with TLR4. HEK 293 cells
were transiently transfected with human MD-2Flag (lane 1), MD-2Flag plus
human TLR4Myc (lane 2), or huMD-2C95Y
Flag
 plus TLR4Myc (lane 3). After
48 h cells were harvested, lysed, and immunoprecipitated with anti-Flag
agarose. Western blot analysis was performed using an anti-Flag mAb or an
anti–c-Myc mAb. Depicted is one representative experiment out of two.
Figure 9. Human wild-type MD-2 but not MD-2C95Y–containing su-
pernatants confer LPS responsiveness on TLR4-transfected cells. HEK
293 cells were transiently cotransfected with either human TLR4
(huTLR4) or empty vector (pcDNA3) plus the pELAM-luc reporter
plasmid. The next day, supernatants from separate dishes of HEK 293
cells that had been transiently transfected overnight with either Flag-
tagged human wild-type MD-2, human mutant MD-2C95Y, or pcDNA3
were transferred to TLR4- or pcDNA3-transfected cells. These superna-
tant-treated cells were then stimulated with LPS (100 ng/ml), IL-1  (2.5
ng/ml), or left untreated. After incubation for 5 h, the total cellular lysates
were assayed for luciferase activity. The results shown are the mean values
of triplicate determinations ( SD) and are representative of three nearly
identical independent experiments.86 A Point Mutation in MD-2 Eliminates Endotoxin Signaling
cently, activation models have been proposed based on the
lipophilic characteristics of lipid A and the observation that
CD14 transfers endotoxin into the lipid bilayer of animal
cells very efficiently. These proposed models held that LPS
signal transduction is initiated by nonspecific perturbations
of lipid bilayer fluidity (36, 37).
The observation that CD14 is a critical component of
LPS responsiveness is now well established, but even this
finding failed to resolve the dilemma of how LPS activates
cells. While CD14 initially appeared to be a highly specific
receptor for endotoxin, investigators quickly learned that
the molecule interacted with a diverse repertoire of bacte-
rial products (38–40). Furthermore, molecular genetic
analysis of human and rodent CD14 demonstrated that this
molecule lacked the ability to finely discriminate between
nearly identical lipid A analogues with pharmacological
properties that are completely different in different species
of mammals (6), suggesting that CD14 lacked the specific-
ity expected of a true LPS receptor. The identification
of TLRs has radically changed this perspective concerning
LPS-induced activation. In contrast to the uncertainty that
previously surrounded our knowledge of the mechanism of
cellular activation by LPS, the mechanism of how TLRs
activate cells may be reasonably straightforward, involving
CD14-mediated ligand–induced conformational changes in
TLR4, receptor complex formation, and engagement of a
subsequent signal transduction cascade.
However, this mechanism of signal transduction remains
largely conjectural, and several important unanswered
questions persist. Most importantly, despite molecular ge-
netic observations suggesting direct binding of LPS to
TLRs (19, 20), clear-cut saturable ligand binding to TLRs
has not been established by conventional techniques. This
is not surprising in view of the difficulties that have been
encountered in the past with LPS-binding assays due to the
heterogeneity of the natural ligand, the difficulties in radio-
labeling LPS to a highly specific activity, and the difficulties
inherent in performing binding assays with a lipid. A po-
tential difficulty associated with the development of ligand-
binding assays for endotoxin–TLR4 interactions is the pos-
sibility that membrane intercalated endotoxin may bind to
the transmembrane region of the signal transduction appa-
ratus (41) in order to initiate signal transduction.
One of the most surprising aspects of TLR4 function ap-
pears to be the requirement of this receptor to engage LPS
together with MD-2, a small, secreted protein. It has not
been clear to what degree cells require MD-2 for LPS re-
sponses. Some investigators have observed LPS-induced
activation in the absence of cotransfection with the gene
for MD-2 (13), although many laboratories have anecdot-
ally reported problems repeating this observation. We pro-
pose that MD-2 is likely to be a biologically active serum
constituent. The fact that supernatants derived from cells
that have been transfected with MD-2 can confer respon-
siveness on cells transfected with only TLR4 (Fig. 9) sup-
ports the idea that MD-2 is secreted in a functionally active
form and can influence cells that ordinarily do not express
this gene product. Normal FBS apparently does not con-
tain sufficient amounts of MD-2 to induce a strong re-
sponse to LPS of cells transfected with TLR4 alone. We
suggest that MD-2 needs to be present in abundance to
have significant biological activity. Accordingly, the previ-
ous differences in LPS responses seen by different investiga-
tors who examined TLR4–transfected cells might, in fact,
be due to differences in the source or the handling of the
bovine serum.
While targeted mutant animals that lack MD-2 expres-
sion have not yet been generated, the loss of function data
presented here support the conclusion that MD-2 is re-
quired for TLR4-mediated cell signaling to occur in re-
sponse to LPS. The mutation in MD-2 identified from the
nonresponder CHO/CD14 cell line is likely to be a critical
clue to the mechanism by which MD-2 functions. Our data
show that MD-2C95Y is apparently capable of binding to the
cell surface and complexing with TLR4 so that the loss of
simple binding of MD-2 to TLR4 does not explain the
phenotype observed. One possibility is that MD-2 may in-
fluence ligand-induced TLR4 oligomerization or may be
necessary for the assembly of an even larger multimeric re-
ceptor complex, and that MD-2C95Y is incapable of these
important functions. Another consideration is that MD-2
might influence the affinity of TLR4 for LPS. An alterna-
tive consideration is the possibility that MD-2 binds LPS di-
rectly, as has recently been proposed (42); LPS–MD-2 com-
plexes might conceivably function as the actual high affinity
ligand for TLR4. Finally, LPS-bound MD-2 may even be
the true ligand for TLR4, a role that is theoretically similar
to the fly peptide spätzle. MD-2C95Y mutant may have lost
its ability to bind LPS or may fail to make the proper con-
formational changes after being bound by endotoxin.
While the mechanism by which MD-2 supports TLR4
function is currently unknown, the importance of MD-2 in
LPS responses is unambiguous, as demonstrated by the re-
markable loss of function of the CHO/CD14 mutant cell
lines and the lack of function of MD2C95Y as a soluble re-
ceptor. These data support the concept that the LPS recep-
tor is a complex consisting of at least CD14, TLR4, and
MD-2, but should not be seen as conclusive evidence that
all of the components of the LPS receptor are currently
known. Activation of TLR4 is thought to result in the ini-
tiation of signal transduction that is shared with the IL-1
receptor. Both MyD88 and TNF receptor–associated factor
6 knockout mice, for example, are defective in LPS- and
IL-1 –induced activation (33, 43). Our data demonstrate
that the “A” complementation group of LPS nonresponder
mutants, represented by clone 7.7, was normally responsive
to stimulation by IL-1   (Figs. 1 and 2). We hypothesize
that in addition to CD14, TLR4, and MD-2, the complete
LPS receptor is comprised of at least one additional gene
product, represented by the mutation in the “A” comple-
mentation group. The hypothesized additional member of
the LPS receptor may prove to be a homologous protein,
such as a TLR, or a proximal molecule immediately adja-
cent to TLR4 in the LPS signal transduction pathway. The
use of a cDNA library to expression clone the lesion in
mutant 7.7 may identify this receptor component.87 Schromm et al.
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